{"authors": [["Bergman", "Philip J", "PJ", "Clinical Studies, VCA, Los Angeles, CA, USA; Katonah Bedford Veterinary Center, Bedford Hills, NY, USA; Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: philip.bergman@vca.com."]], "date": "2017-12-07", "id": "29224713", "text": "The ideal cancer immunotherapy agent should be able to discriminate between cancer and normal cells, be potent enough to kill small or large numbers of tumor cells, and be able to prevent recurrence of the tumor. Tumor immunology and immunotherapy are among the most exciting and rapidly expanding fields; cancer immunotherapy is now recognized as a pillar of treatment alongside traditional modalities. This article highlights approaches that seem to hold particular promise in human clinical trials and many that have been tested in veterinary medicine.", "doi": "10.1016/j.cvsm.2017.10.004", "title": "Veterinary Oncology Immunotherapies.", "journal": ["The Veterinary clinics of North America. Small animal practice", "Vet. Clin. North Am. Small Anim. Pract."]}